Prognostic Value of Interim 18F-DOPA and 18F-FDG PET/CT Findings in Stage 3–4 Pediatric Neuroblastoma
Authors:
- 1 January 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 47 (1) , 21-25
Abstract
Purpose: This retrospective study aimed to determine the prognostic value of imaging parameters derived from midtherapy 18F-fluorodihydroxyphenylalanine (18F-DOPA) and 18F-FDG PET in pediatric patients with stage 3–4 neuroblastoma. Methods: We enrolled 32 stage 3–4 pediatric neuroblastoma patients who underwent 18F-DOPA and 18F-FDG PET/CT scans before and after 3 chemotherapy cycles. We measured metabolic and volumetric parameters and applied a metabolic burden scoring system to evaluate the primary tumor extent and soft tissue metastases and that of bone/bone marrow involvement. The associations between these parameters and clinical outcomes were investigated. Results: Over a median follow-up period of 47 months (range, 3–137 months), 16 patients experienced disease progression, and 13 died. After adjustment for clinical factors, multivariate Cox proportional hazard models showed that interim tumor FDG/FDOPA SUVmax (hazard ratio [HR], 5.94; 95% confidence interval [CI], 1.10–34.98) and interim FDOPA whole-body metabolic burden scores (WBMB) (HR, 7.30; 95% CI, 1.50–35.50) were significant prognostic factors for overall survival (OS). Only interim FDOPA WBMB scores (HR, 7.05; 95% CI, 1.02–48.7) were predictive of progression-free survival. Based on median cutoff values, prognosis (OS and progression-free survival) was significantly associated with an interim FDOPA WBMB score ≥21.92 (all P < 0.05) and interim tumor FDG/FDOPA (SUVmax) score ≥0.57 with poor OS (P < 0.05). Conclusions: Our results indicate that midtreatment FDG and FDOPA PET/CT could serve as prognostic markers in stage 3–4 neuroblastoma patients.Keywords
This publication has 26 references indexed in Scilit:
- Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trialThe Lancet Oncology, 2013
- 18F-FDG PET/CT and 123I-Metaiodobenzylguanidine Imaging in High-Risk Neuroblastoma: Diagnostic Comparison and Survival AnalysisJournal of Nuclear Medicine, 2011
- Outcome after Reduced Chemotherapy for Intermediate-Risk NeuroblastomaNew England Journal of Medicine, 2010
- Recent Advances in NeuroblastomaNew England Journal of Medicine, 2010
- Neuroblastoma: Biology, Prognosis, and TreatmentHematology/Oncology Clinics of North America, 2010
- 123I-MIBG Scintigraphy and 18F-FDG PET in NeuroblastomaJournal of Nuclear Medicine, 2009
- The Effects of Carbidopa on Uptake of 6-18F-Fluoro-L-DOPA in PET of Pheochromocytoma and Extraadrenal Abdominal ParagangliomaJournal of Nuclear Medicine, 2007
- Neuroblastoma: biological insights into a clinical enigmaNature Reviews Cancer, 2003
- Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic AcidNew England Journal of Medicine, 1999
- Amplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease StageScience, 1984